SITE-DIRECTED MODIFICATION OF FVIII

This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties. 本发明...

Full description

Saved in:
Bibliographic Details
Main Authors STRAUSS JONATHAN S, TJANDRA HENDRI, BARNETT THOMAS, MEI BAISONG, WANG DEQIAN, CHEN JLANMIN, MURPHY JOHN E, PAN CLARK Q, TANG LIANG
Format Patent
LanguageChinese
English
Published 13.07.2016
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties. 本发明涉及FVIII的位点定向修饰，还涉及因子VIII突变蛋白，其在非N?末端胺的预定位点共价结合到个或多个生物相容的聚合物，如聚乙二醇上。突变蛋白缀合物保留了FVIII前凝血剂活性，且具有提高的药物代谢动力学性质。
Bibliography:Application Number: CN201610201090